Relapse Rate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda TSE4502NYSETAK today announced the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy after stabilization with intravenous immunoglobulin therapy IVIG.

If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous…

TakedaTSE4502NYSETAK today announced full results from the pivotal Phase 3 ADVANCECIDP 1 clinical trial investigating HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy CIDP.

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) - read this article along with other careers information, tips and advice on BioSpace

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a...